Edwards Lifesciences (NYSE:EW) Upgraded by JPMorgan Chase & Co. to Overweight Rating

Edwards Lifesciences (NYSE:EW) was upgraded by equities researchers at JPMorgan Chase & Co. from a “neutral” rating to an “overweight” rating in a report released on Thursday,Benzinga reports. The firm presently has a $100.00 target price on the medical research company’s stock, up from their prior target price of $90.00. JPMorgan Chase & Co.‘s price objective points to a potential upside of 17.85% from the company’s current price.

EW has been the topic of a number of other reports. Mizuho lifted their price objective on Edwards Lifesciences from $90.00 to $100.00 and gave the stock an “outperform” rating in a research report on Friday, October 31st. Raymond James Financial raised Edwards Lifesciences from a “market perform” rating to an “outperform” rating and set a $96.00 price target for the company in a research note on Monday, November 3rd. The Goldman Sachs Group set a $104.00 price objective on shares of Edwards Lifesciences and gave the company a “buy” rating in a research report on Friday, October 31st. Truist Financial set a $92.00 target price on shares of Edwards Lifesciences and gave the stock a “hold” rating in a research report on Friday, December 5th. Finally, Jefferies Financial Group set a $98.00 price target on shares of Edwards Lifesciences and gave the stock a “buy” rating in a research note on Wednesday, October 29th. Three research analysts have rated the stock with a Strong Buy rating, fourteen have issued a Buy rating, nine have assigned a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat.com, the company has an average rating of “Moderate Buy” and an average target price of $93.95.

Edwards Lifesciences Price Performance

Shares of Edwards Lifesciences stock opened at $84.85 on Thursday. The company’s fifty day simple moving average is $82.10 and its two-hundred day simple moving average is $79.18. Edwards Lifesciences has a 12-month low of $65.94 and a 12-month high of $87.89. The firm has a market cap of $49.24 billion, a PE ratio of 36.58, a price-to-earnings-growth ratio of 3.84 and a beta of 0.97. The company has a quick ratio of 3.29, a current ratio of 4.00 and a debt-to-equity ratio of 0.06.

Edwards Lifesciences (NYSE:EW) last issued its quarterly earnings data on Thursday, October 30th. The medical research company reported $0.67 EPS for the quarter, beating the consensus estimate of $0.59 by $0.08. Edwards Lifesciences had a net margin of 23.25% and a return on equity of 14.70%. The firm had revenue of $1.55 billion during the quarter, compared to the consensus estimate of $1.49 billion. During the same period in the prior year, the firm posted $0.67 earnings per share. The company’s quarterly revenue was up 14.7% compared to the same quarter last year. Edwards Lifesciences has set its FY 2025 guidance at 2.560-2.620 EPS and its Q4 2025 guidance at 0.580-0.640 EPS. As a group, equities analysts expect that Edwards Lifesciences will post 2.45 EPS for the current year.

Insiders Place Their Bets

In other news, VP Daniel J. Lippis sold 1,019 shares of the business’s stock in a transaction that occurred on Friday, December 12th. The stock was sold at an average price of $84.03, for a total value of $85,626.57. Following the sale, the vice president directly owned 22,002 shares of the company’s stock, valued at $1,848,828.06. The trade was a 4.43% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. Also, VP Donald E. Bobo, Jr. sold 11,386 shares of the firm’s stock in a transaction that occurred on Friday, December 12th. The shares were sold at an average price of $83.76, for a total value of $953,691.36. Following the transaction, the vice president directly owned 38,970 shares of the company’s stock, valued at approximately $3,264,127.20. This trade represents a 22.61% decrease in their position. The disclosure for this sale is available in the SEC filing. Over the last quarter, insiders have sold 45,465 shares of company stock worth $3,804,610. 1.29% of the stock is currently owned by company insiders.

Institutional Investors Weigh In On Edwards Lifesciences

Several hedge funds have recently added to or reduced their stakes in EW. Norges Bank purchased a new position in shares of Edwards Lifesciences in the 2nd quarter worth about $580,640,000. DZ BANK AG Deutsche Zentral Genossenschafts Bank Frankfurt am Main increased its stake in Edwards Lifesciences by 111.2% during the 2nd quarter. DZ BANK AG Deutsche Zentral Genossenschafts Bank Frankfurt am Main now owns 9,129,357 shares of the medical research company’s stock valued at $714,006,000 after purchasing an additional 4,805,819 shares in the last quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC raised its holdings in Edwards Lifesciences by 278.3% in the third quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 5,584,646 shares of the medical research company’s stock worth $434,318,000 after buying an additional 4,108,270 shares during the last quarter. Marshall Wace LLP raised its holdings in Edwards Lifesciences by 127.5% in the second quarter. Marshall Wace LLP now owns 6,895,579 shares of the medical research company’s stock worth $539,303,000 after buying an additional 3,864,908 shares during the last quarter. Finally, Viking Global Investors LP bought a new position in shares of Edwards Lifesciences in the third quarter worth approximately $238,688,000. 79.46% of the stock is owned by institutional investors.

About Edwards Lifesciences

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.